A recent narrative review further summarized that the mainstay treatments of Diabetic kidney disease are the renin–angiotensin system (RAS) inhibitors, SGLT2 inhibitors, incretin-based therapeutic agents, and mineralocorticoid receptor antagonists (MRA) [16]. This evidence concerns the gene SLC5A2 and diabetic kidney disease.